Google
SRZN Stock Price & Analysis — Surrozen Inc (Healthcare >> Biotechnology)
SRZN FAQ
What is SRZN's P/E ratio?
Surrozen Inc (SRZN) currently trades at a P/E ratio of 6.08.
What is SRZN's ROE?
Surrozen Inc reports a Return on Equity (ROE) of 123.16%.
What is SRZN's dividend yield?
Surrozen Inc offers a dividend yield of 0.00%.
What is SRZN's Quality Score?
Our AI rates SRZN's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy SRZN?
Our AI Timing Score for SRZN is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does SRZN belong to?
Surrozen Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
SRZN AI Analysis Summary
Our AI summary for SRZN: Surrozen Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 6.08, ROE of 123.16%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 22.21
Price
1.38
(6.63%)
Day Change
|
|
|---|
SRZN, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
54% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 22.21 |
| PBV / Sector |
-0.87 / 5.20
|
| Earning Per Share | -31.46 |
| PE / Sector |
6.08 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
0.14 / 1.22
GREAT
|
| Average 1M Daily Value |
5.14 M
GREAT
|
| Average 1W Daily Value |
9.35 M
|
| Timing Factors |
|
71% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
60% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 08:00:31 |
| Symbol | SRZN |
| Name | SURROZEN INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 11.61 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 241.84 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Phone: 650 489 9000
Website: https://www.surrozen.com
Sector: Healthcare >> Biotechnology
Description: Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap